We need your help now

Support from readers like you keeps The Journal open.

You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.

If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.

Called Off

A huge drug company merger deal has been cancelled

New US tax rules were introduced on Monday which may have made the deal more unfavourable.

A PROPOSED MERGER deal between two pharmaceutical companies, which would have been the biggest of its kind in history, has reportedly been cancelled.

CNBC reports that the proposed deal between US pharmaceutical giant Pfizer and the smaller drug company Allergen (which has its headquarters in Dublin) has been called off, according to sources.

The deal – which would have seen the New York-based Pfizer move its tax base to Ireland – would have been the largest “tax inversion” deal in history.

This is a complex merger whereby the smaller, Dublin-headquartered Allergan would take over Pfizer. With the company being renamed Pfizer PLC.

The confusing and complicated mergers have been strongly criticised in the past as ways for large companies to avoid paying tax.

New rules

The decision to end the deal comes as the US Treasury Department announced a new package of rules on Monday aimed at making these tax inversion deals less financially appealing.

The new regulations, the third round that the Treasury has put forward on inversions, seek to limit internal corporate borrowing that shifts profits out of the United States.

On Monday night, Pfizer and Allergan issued a joint statement saying that they are reviewing the new Treasury rules and would not speculate on their potential impact.

Now, according to reports it seems that the board of Pfizer has voted against the proposed merger with Allergen.

CNBC also reports that Pfizer may need to pay Allergen a $400 million break fee in accordance with the agreement of the merger.

- With reporting from AFP

Read: A €160 billion drug company deal could be in jeopardy due to new US financial rules

Read: Americans are queuing up to slam Pfizer’s tax-inspired move to Ireland

Readers like you are keeping these stories free for everyone...
A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article. Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation.

Your Voice
Readers Comments
    Submit a report
    Please help us understand how this comment violates our community guidelines.
    Thank you for the feedback
    Your feedback has been sent to our team for review.